Supercharged immune cells take on Hard-to-Treat cancers
NCT ID NCT07621471
First seen Jun 03, 2026 · Last updated Jun 19, 2026 · Updated 4 times
Summary
This early-phase study tests a new treatment using specially engineered natural killer (NK) cells boosted with IL-15 to fight advanced solid tumors that have not responded to standard therapies. About 12 adults aged 18-70 with metastatic or recurrent cancers like breast, liver, or lung cancer will receive the cells to see if it is safe and can shrink tumors. The goal is to control the disease, not cure it, and patients will be monitored for side effects and how long the benefit lasts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Xinqiao Hospital
Chongqing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.